Z
9.00
-0.28 (-3.02%)
| Previous Close | 9.28 |
| Open | 9.25 |
| Volume | 909,746 |
| Avg. Volume (3M) | 562,946 |
| Market Cap | 492,116,416 |
| Price / Earnings (Forward) | 5.47 |
| Price / Sales | 10.98 |
| Price / Book | 12.04 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -226.64% |
| Operating Margin (TTM) | -26.28% |
| Diluted EPS (TTM) | -1.94 |
| Quarterly Revenue Growth (YOY) | 495.70% |
| Total Debt/Equity (MRQ) | 150.74% |
| Current Ratio (MRQ) | 3.02 |
| Operating Cash Flow (TTM) | -61.72 M |
| Levered Free Cash Flow (TTM) | -39.23 M |
| Return on Assets (TTM) | -27.73% |
| Return on Equity (TTM) | -204.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Zevra Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.0 |
| Average | 1.63 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.62% |
| % Held by Institutions | 65.39% |
| 52 Weeks Range | ||
| Median | 25.00 (177.78%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 25.00 (177.78%) | Buy | 8.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 May 2025 | Announcement | Zevra Announces Final Results of 2025 Annual Meeting of Stockholders |
| 21 May 2025 | Announcement | All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees |
| 13 May 2025 | Announcement | Zevra Reports First Quarter 2025 Financial Results and Corporate Update |
| 06 May 2025 | Announcement | Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call |
| 01 May 2025 | Announcement | Zevra Therapeutics to Participate in the Citizens Life Science Conference |
| 21 Apr 2025 | Announcement | Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders |
| 17 Apr 2025 | Announcement | Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism |
| 07 Apr 2025 | Announcement | Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |